• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多中心评估淋巴结密度和淋巴结分期以预测接受根治性膀胱切除术的膀胱癌患者的疾病特异性生存率

Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy.

作者信息

van Gennep Erik J, Claps Francesco, Bostrom Peter J, Shariat Shahrokh F, Neuzillet Yann, Zlotta Alexandre R, Trombetta Carlo, Eckstein Markus, Mertens Laura S, Bussani Rossana, Burger Maximilian, Boormans Joost L, Wullich Bernd, Hartmann Arndt, Mayr Roman, Pavan Nicola, Bartoletti Riccardo, Mir M Carmen, Pouessel Damien, van der Hoeven John, van der Kwast Theo H, Allory Yves, Zuiverloon Tahlita C M, Lotan Yair, van Rhijn Bas W G

机构信息

Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Department of Urology, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Bladder Cancer. 2024 Jun 18;10(2):119-132. doi: 10.3233/BLC-230086. eCollection 2024.

DOI:10.3233/BLC-230086
PMID:39131875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11308645/
Abstract

BACKGROUND

Prognostic tools in pathological-node (pN) patients after radical cystectomy (RC) are needed.

OBJECTIVES

To evaluate the prognostic impact of lymph node (LN)-density on disease-specific survival (DSS) in patients with bladder cancer (BC) undergoing RC with pelvic lymph node dissection.

METHODS

We analyzed a multi-institutional cohort of 1169 patients treated with upfront RC for cT1-4aN0M0 urothelial BCat nine centers. LN-densitywas calculated as the ratio of the number of positive LNs×100% to the number of LNs removed. The optimal LN-density cut-off value was defined by creating a time-dependent receiver operating characteristic (ROC) curve in pN patients. Univariable and multivariable Cox' regression analyses were used to assess the effect of conventional Tumor Nodes Metastasis (TNM) nodal staging system, LN-density and other LN-related variables on DSS in the pN-positive cohort.

RESULTS

Of the 1169 patients, 463 (39.6%) patients had LN-involvement. The area under the ROC curve was 0.60 and the cut-off for LN-density was set at 20%, 223 of the pN-positive patients (48.2%) had a LN-density ≥ 20%. In multivariable models, the number of LN-metastases (HR 1.03, p = 0.005) and LN-density, either as continuous (HR 1.01, p = 0.013) or as categorical variable (HR 1.37, p = 0.014), were independently associated with worse DSS, whereas pN-stage was not.

CONCLUSIONS

LN-density ≥ 20% was an independent predictor of worse DSS in BC patients with LN-involvement at RC. The integration of LN-density and other LN-parameters rather than only conventional pN-stage may contribute to a more refined risk-stratification in BC patients with nodal involvement.

摘要

背景

根治性膀胱切除术(RC)后病理分期为淋巴结阳性(pN)的患者需要预后评估工具。

目的

评估淋巴结(LN)密度对接受盆腔淋巴结清扫的膀胱癌(BC)患者行RC后的疾病特异性生存(DSS)的预后影响。

方法

我们分析了来自九个中心的1169例接受 upfront RC 治疗的 cT1-4aN0M0 尿路上皮 BC 患者的多机构队列。LN 密度计算为阳性 LN 数量×100%与切除的 LN 数量的比值。通过在 pN 患者中创建时间依赖性受试者操作特征(ROC)曲线来定义最佳 LN 密度临界值。采用单变量和多变量 Cox 回归分析评估传统肿瘤淋巴结转移(TNM)淋巴结分期系统、LN 密度和其他 LN 相关变量对 pN 阳性队列中 DSS 的影响。

结果

1169例患者中,463例(39.6%)有LN转移。ROC曲线下面积为0.60,LN密度临界值设定为20%,223例pN阳性患者(48.2%)的LN密度≥20%。在多变量模型中,LN转移数量(HR 1.03,p = 0.005)和LN密度,无论是作为连续变量(HR 1.01,p = 0.013)还是分类变量(HR 1.37,p = 0.014),均与较差的DSS独立相关,而pN分期则不然。

结论

LN密度≥20%是RC时伴有LN转移的BC患者DSS较差的独立预测因素。整合LN密度和其他LN参数而非仅传统的pN分期可能有助于对有淋巴结受累的BC患者进行更精确的风险分层。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f76/11308645/8410351eda8b/blc-10-blc230086-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f76/11308645/7430daa58d52/blc-10-blc230086-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f76/11308645/8410351eda8b/blc-10-blc230086-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f76/11308645/7430daa58d52/blc-10-blc230086-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f76/11308645/8410351eda8b/blc-10-blc230086-g002.jpg

相似文献

1
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy.多中心评估淋巴结密度和淋巴结分期以预测接受根治性膀胱切除术的膀胱癌患者的疾病特异性生存率
Bladder Cancer. 2024 Jun 18;10(2):119-132. doi: 10.3233/BLC-230086. eCollection 2024.
2
Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.结外侵犯是膀胱癌伴淋巴结转移患者的一个强有力的预后因素。
Eur Urol. 2013 Nov;64(5):837-45. doi: 10.1016/j.eururo.2012.07.026. Epub 2012 Jul 20.
3
Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy.术前白蛋白-纤维蛋白原比值(AFR)对接受根治性膀胱切除术治疗的膀胱癌患者的预后价值。
Urol Oncol. 2021 Dec;39(12):835.e9-835.e17. doi: 10.1016/j.urolonc.2021.04.026. Epub 2021 May 26.
4
Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy.膀胱癌的临床淋巴结病:接受根治性膀胱切除术而未接受新辅助化疗的患者的横断面成像表现和肿瘤学结局的跨大西洋合作。
Eur Urol Focus. 2018 Mar;4(2):245-251. doi: 10.1016/j.euf.2016.11.005. Epub 2016 Nov 23.
5
Lymph node density vs. the American Joint Committee on Cancer TNM nodal staging system in node-positive bladder cancer in patients undergoing extended or super-extended pelvic lymphadenectomy.接受扩大或超扩大盆腔淋巴结清扫术的淋巴结阳性膀胱癌患者的淋巴结密度与美国癌症联合委员会TNM淋巴结分期系统的比较
Urol Oncol. 2017 Apr;35(4):151.e1-151.e7. doi: 10.1016/j.urolonc.2016.06.021. Epub 2017 Jan 27.
6
Molecular lymph node staging for bladder cancer patients undergoing radical cystectomy with pelvic lymph node dissection.膀胱癌患者行根治性膀胱切除术加盆腔淋巴结清扫术的分子淋巴结分期。
Urol Oncol. 2020 Jul;38(7):639.e11-639.e19. doi: 10.1016/j.urolonc.2020.01.018. Epub 2020 Mar 4.
7
The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy.变异组织学分化对接受根治性膀胱切除术的淋巴结阳性膀胱癌患者的结外扩散及生存的影响。
Surg Oncol. 2019 Mar;28:208-213. doi: 10.1016/j.suronc.2019.01.008. Epub 2019 Jan 30.
8
Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy.在接受根治性膀胱切除术的淋巴结阴性膀胱癌患者中,盆腔淋巴结清扫术时解剖的淋巴结数量与癌症特异性生存的关系。
Ann Surg Oncol. 2011 Jul;18(7):2018-25. doi: 10.1245/s10434-010-1538-6. Epub 2011 Jan 19.
9
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.根治性膀胱切除术治疗的尿路上皮膀胱癌中变异组织学的预后影响
BJU Int. 2023 Aug;132(2):170-180. doi: 10.1111/bju.15984. Epub 2023 Feb 20.
10
Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.新辅助化疗治疗隐匿性淋巴结转移膀胱癌患者预后不良。
BJU Int. 2018 Oct;122(4):627-632. doi: 10.1111/bju.14242. Epub 2018 May 4.

引用本文的文献

1
Using machine learning for predicting cancer-specific mortality in bladder cancer patients undergoing radical cystectomy: a SEER-based study.使用机器学习预测接受根治性膀胱切除术的膀胱癌患者的癌症特异性死亡率:一项基于监测、流行病学和最终结果(SEER)数据库的研究
BMC Cancer. 2025 Mar 21;25(1):523. doi: 10.1186/s12885-025-13942-2.

本文引用的文献

1
Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer.在pN+膀胱癌患者中,选择根治性膀胱切除术后基于顺铂辅助化疗的最佳候选者。
Eur Urol Oncol. 2022 Dec;5(6):722-725. doi: 10.1016/j.euo.2022.04.001. Epub 2022 Jun 15.
2
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.浸润性膀胱癌的预后标志物:FGFR3突变状态与P53和KI-67表达的比较:一项针对1058例根治性膀胱切除术患者的多中心、多实验室分析
Urol Oncol. 2022 Mar;40(3):110.e1-110.e9. doi: 10.1016/j.urolonc.2021.10.010. Epub 2021 Dec 11.
3
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
辅助化疗治疗肌层浸润性膀胱癌:随机对照试验个体参与者数据的系统评价和荟萃分析。
Eur Urol. 2022 Jan;81(1):50-61. doi: 10.1016/j.eururo.2021.09.028. Epub 2021 Nov 19.
4
Molecular markers of systemic therapy response in urothelial carcinoma.尿路上皮癌全身治疗反应的分子标志物
Asian J Urol. 2021 Oct;8(4):376-390. doi: 10.1016/j.ajur.2021.05.001. Epub 2021 May 14.
5
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival.与根治性膀胱切除术时阳性手术切缘位置相关的危险因素及其对膀胱癌生存的影响。
World J Urol. 2021 Dec;39(12):4363-4371. doi: 10.1007/s00345-021-03776-5. Epub 2021 Jul 1.
6
Pathological reporting of cystectomy lymph nodes: a retrospective analysis of experience in Paris.膀胱切除术淋巴结的病理报告:巴黎经验的回顾性分析。
World J Urol. 2021 Nov;39(11):4029-4035. doi: 10.1007/s00345-021-03630-8. Epub 2021 Mar 20.
7
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.欧洲泌尿外科学会肌层浸润性和转移性膀胱癌指南:2020 年指南摘要。
Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29.
8
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌(TaT1 和原位癌)指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
9
Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients.宿主分期:为根治性膀胱切除术患者进行个体化风险评估。
Eur Urol Oncol. 2018 Sep;1(4):292-304. doi: 10.1016/j.euo.2018.05.010. Epub 2018 Jun 19.
10
The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy.变异组织学分化对接受根治性膀胱切除术的淋巴结阳性膀胱癌患者的结外扩散及生存的影响。
Surg Oncol. 2019 Mar;28:208-213. doi: 10.1016/j.suronc.2019.01.008. Epub 2019 Jan 30.